Jon E Kuehler

Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein–Protein Interaction

J. Christensen, J. Lawson, Jacob R. Haling, 2022, Journal of medicinal chemistry.

Azaindole hydroxamic acids are potent HIV-1 integrase inhibitors.

A. Kuki, S. Butler, S. V. Rahavendran, 2009, Journal of medicinal chemistry.

Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of MTAP-Deleted Cancers.

J. Christensen, J. Lawson, P. Olson, 2022, Journal of medicinal chemistry.

Azaindole N-methyl hydroxamic acids as HIV-1 integrase inhibitors-II. The impact of physicochemical properties on ADME and PK.

A. Kuki, S. Butler, Buwen Huang, 2010, Bioorganic & medicinal chemistry letters.

Fragment optimization and elaboration strategies – the discovery of two lead series of PRMT5/MTA inhibitors from five fragment hits

J. Christensen, J. Lawson, Misbha Ud Din Ahmad, 2022, RSC medicinal chemistry.

Design and evaluation of achiral, non-atropisomeric 4-(aminomethyl)phthalazin-1(2H)-one derivatives as novel PRMT5/MTA inhibitors.

J. Christensen, P. Olson, A. Ivetac, 2022, Bioorganic & medicinal chemistry.

Design and synthesis of novel N-hydroxy-dihydronaphthyridinones as potent and orally bioavailable HIV-1 integrase inhibitors.

A. Kuki, S. Butler, Guy A. McClellan, 2011, Journal of medicinal chemistry.